File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.bbcan.2012.05.006
- Scopus: eid_2-s2.0-84862683338
- PMID: 22683405
- WOS: WOS:000310104900008
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Regulators of mammalian Hippo pathway in cancer
Title | Regulators of mammalian Hippo pathway in cancer |
---|---|
Authors | |
Keywords | Hippo Signaling Lats1/2 Mst1/2 Regulators Solid Cancer Yap |
Issue Date | 2012 |
Publisher | Elsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/bbaroco |
Citation | Biochimica Et Biophysica Acta - Reviews On Cancer, 2012, v. 1826 n. 2, p. 357-364 How to Cite? |
Abstract | Hippo pathway, originally discovered in Drosophila, is responsible for organ size control. The pathway is conserved in mammals and has a significant role in restraining cancer development. Regulating the Hippo pathway thus represents a potential therapeutic approach to treat cancer, which however requires deep understanding of the targeted pathway. Despite our limited knowledge on the pathway, there are increasing discoveries of new molecules that regulate and modulate the Hippo downstream signaling particularly in various solid malignancies, from extracellular stimuli or via pathway crosstalk. Herein, we discuss the roles of newly identified and key regulators that connect with core components (MST1/2, LATS1/2, SAV1, and MOB1) and downstream effector (YAP) in the Hippo pathway having an important role in cancer development and progression. Understanding of the mammalian Hippo pathway regulation may shed new insights to allow us selecting the right oncogenic targets and designing effective drugs for cancer treatments. © 2012 Elsevier B.V. |
Persistent Identifier | http://hdl.handle.net/10722/173029 |
ISSN | 2023 Impact Factor: 9.7 2023 SCImago Journal Rankings: 2.838 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Liu, AM | en_US |
dc.contributor.author | Wong, KF | en_US |
dc.contributor.author | Jiang, X | en_US |
dc.contributor.author | Qiao, Y | en_US |
dc.contributor.author | Luk, JM | en_US |
dc.date.accessioned | 2012-10-30T06:26:40Z | - |
dc.date.available | 2012-10-30T06:26:40Z | - |
dc.date.issued | 2012 | en_US |
dc.identifier.citation | Biochimica Et Biophysica Acta - Reviews On Cancer, 2012, v. 1826 n. 2, p. 357-364 | en_US |
dc.identifier.issn | 0304-419X | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/173029 | - |
dc.description.abstract | Hippo pathway, originally discovered in Drosophila, is responsible for organ size control. The pathway is conserved in mammals and has a significant role in restraining cancer development. Regulating the Hippo pathway thus represents a potential therapeutic approach to treat cancer, which however requires deep understanding of the targeted pathway. Despite our limited knowledge on the pathway, there are increasing discoveries of new molecules that regulate and modulate the Hippo downstream signaling particularly in various solid malignancies, from extracellular stimuli or via pathway crosstalk. Herein, we discuss the roles of newly identified and key regulators that connect with core components (MST1/2, LATS1/2, SAV1, and MOB1) and downstream effector (YAP) in the Hippo pathway having an important role in cancer development and progression. Understanding of the mammalian Hippo pathway regulation may shed new insights to allow us selecting the right oncogenic targets and designing effective drugs for cancer treatments. © 2012 Elsevier B.V. | en_US |
dc.language | eng | en_US |
dc.publisher | Elsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/bbaroco | en_US |
dc.relation.ispartof | Biochimica et Biophysica Acta - Reviews on Cancer | en_US |
dc.subject | Hippo Signaling | en_US |
dc.subject | Lats1/2 | en_US |
dc.subject | Mst1/2 | en_US |
dc.subject | Regulators | en_US |
dc.subject | Solid Cancer | en_US |
dc.subject | Yap | en_US |
dc.title | Regulators of mammalian Hippo pathway in cancer | en_US |
dc.type | Article | en_US |
dc.identifier.email | Luk, JM: jmluk@hkucc.hku.hk | en_US |
dc.identifier.authority | Luk, JM=rp00349 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1016/j.bbcan.2012.05.006 | en_US |
dc.identifier.pmid | 22683405 | - |
dc.identifier.scopus | eid_2-s2.0-84862683338 | en_US |
dc.identifier.volume | 1826 | en_US |
dc.identifier.issue | 2 | en_US |
dc.identifier.spage | 357 | en_US |
dc.identifier.epage | 364 | en_US |
dc.identifier.isi | WOS:000310104900008 | - |
dc.publisher.place | Netherlands | en_US |
dc.identifier.scopusauthorid | Liu, AM=36134439500 | en_US |
dc.identifier.scopusauthorid | Wong, KF=49362744900 | en_US |
dc.identifier.scopusauthorid | Jiang, X=55258295200 | en_US |
dc.identifier.scopusauthorid | Qiao, Y=55258212400 | en_US |
dc.identifier.scopusauthorid | Luk, JM=7006777791 | en_US |
dc.identifier.citeulike | 10770148 | - |
dc.identifier.issnl | 0304-419X | - |